Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity
- 9 March 2013
- journal article
- research article
- Published by Springer Nature in Quality of Life Research
- Vol. 22 (9) , 2489-2499
Abstract
The Physician Global Assessment (PGA) is a key measure of psoriasis frequently used in clinical trials. A psychometric validation of a three-item (erythema, induration, and scaling) PGA scale was performed using Phase 2 data. Confirmatory factor analysis (CFA) tested the PGA measurement model and appropriateness of equal weighting of the items. PGA test–retest reliability was assessed by estimating the intraclass correlation coefficient (ICC). Internal consistency reliability was gauged by calculating Cronbach’s coefficient α (CCα). Clinically important difference (CID) was defined using the repeated measures model to estimate the relationship between PGA and Patient Global Assessment (PtGA). Known-group, convergent, and divergent validity for the PGA were also assessed. 197 patients with psoriasis were randomized to tofacitinib 2, 5, 15 mg twice daily, or placebo. CFA demonstrated that the PGA measurement model fitted the data using equal weighting of the PGA items. The PGA scale demonstrated good test–retest reliability (ICC > 0.7) and internal consistency reliability (CCα > 0.8). The CID for PGA was estimated at 0.52 (95 % confidence interval: 0.47, 0.56). A robust monotonic relationship between PGA and Psoriasis Area and Severity Index (PASI) data substantiated known-group validity. Relatively high correlations of PGA with PASI and PtGA data (all correlations >0.5 except at baseline) supported convergent validity; relatively low correlations of PGA with the Pain/Discomfort Assessment and the Ocular Comfort Index supported divergent validity. The three-item PGA scale has sound psychometric properties with respect to reliability and validity, with equal weighting of the items being appropriate.Keywords
This publication has 25 references indexed in Scilit:
- Interpretation of patient-reported outcomesStatistical Methods in Medical Research, 2013
- Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging studyBritish Journal of Dermatology, 2012
- Poor metrics and lost opportunityJournal of the American Academy of Dermatology, 2010
- How Good Are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic ReviewJournal of Investigative Dermatology, 2010
- Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversiesClinics in Dermatology, 2010
- Validation of the Erection Hardness ScoreThe Journal of Sexual Medicine, 2007
- Measures used in specifying psoriasis lesion(s), global disease and quality of life: A systematic reviewJournal of Dermatological Treatment, 2007
- Psoriasis assessment tools in clinical trialsAnnals of the Rheumatic Diseases, 2005
- Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global AssessmentJournal of the American Academy of Dermatology, 2004
- Randomized Clinical Trials for Psoriasis 1977–2000: The EDEN SurveyJournal of Investigative Dermatology, 2003